A
Anna P. Durbin
Researcher at Johns Hopkins University
Publications - 130
Citations - 7977
Anna P. Durbin is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Dengue virus & Dengue vaccine. The author has an hindex of 45, co-authored 121 publications receiving 6770 citations. Previous affiliations of Anna P. Durbin include Walter Reed Army Institute of Research & Government of the United States of America.
Papers
More filters
Journal ArticleDOI
Prospects for a dengue virus vaccine.
TL;DR: The unique immunological concerns in dengue virus vaccine development are discussed and the current prospects for the development of an acceptable vaccine are discussed, with a goal that is likely to be reached in the near future.
Journal ArticleDOI
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Yimin Wu,Ruth D. Ellis,Donna Shaffer,Erica Fontes,Elissa Malkin,Siddhartha Mahanty,Michael P. Fay,David L. Narum,Kelly M. Rausch,Aaron P. Miles,Joan Aebig,Andrew C. Orcutt,Olga Muratova,Guanhong Song,Lynn Lambert,Daming Zhu,Kazutoyo Miura,Carole A. Long,Allan Saul,Louis H. Miller,Anna P. Durbin +20 more
TL;DR: It is feasible to induce transmission blocking immunity in humans using the Pfs25/ISA 51 vaccine, but these vaccines are unexpectedly reactogenic for further development.
Journal ArticleDOI
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
Isaac See,John R. Su,Allison Lale,Emily Jane Woo,Alice Guh,Tom T. Shimabukuro,Michael B. Streiff,Agam K Rao,Allison P. Wheeler,Suzanne F. Beavers,Anna P. Durbin,Kathryn M. Edwards,Elaine R. Miller,Theresa Harrington,Adamma Mba-Jonas,Narayan Nair,Duong T. Nguyen,Kawsar R. Talaat,Victor C. Urrutia,Shannon C. Walker,C. Buddy Creech,Thomas A. Clark,Frank DeStefano,Karen R. Broder +23 more
TL;DR: In this paper, the authors describe reports of CVST with thrombocytopenia following Ad26.COV2.S vaccination in Europe following receipt of the ChAdOx1 nCoV-19 vaccine, which uses a chimpanzee adenoviral vector.
Journal ArticleDOI
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
Anna P. Durbin,Ruth A. Karron,Wellington Sun,David W. Vaughn,Mary J. Reynolds,John Perreault,Bhavin Thumar,Ruhe Men,Ching-Juh Lai,William R. Elkins,Robert M. Chanock,Brian R. Murphy,Stephen S. Whitehead +12 more
TL;DR: The low level of reactogenicity and high degree of immunogenicity of this vaccine candidate warrant its further evaluation and its use to create chimeric vaccine viruses expressing the structural genes of dengue virus types 1, 2, and 3.
Journal ArticleDOI
Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
Elissa Malkin,David Diemert,Julie H. McArthur,John R. Perreault,Aaron P. Miles,Birgitte Giersing,Gregory E. D. Mullen,Andrew C. Orcutt,Olga Muratova,May Awkal,Hong Zhou,Jin Wang,Anthony W. Stowers,Carole A. Long,Siddhartha Mahanty,Louis H. Miller,Allan Saul,Anna P. Durbin +17 more
TL;DR: This is the first AMA1 vaccine candidate to elicit functional immune responses in malaria-naïve humans, and the results support the further development of this vaccine.